QDIS Blog

A blog about chemistry, drug development, science, and technology

December 11, 2006

Gilead in Trouble over HIV Drug Marketing

by @ 3:08 pm.  Filed under Pharma News, Pharma

Seems Gilead may be in trouble over off-label marketing of its HIV drugs. The practice of prescribing drugs for off-label use is legal but the marketing of drugs to doctors for off-label use is prohibited.

MercuryNews.com | 12/07/2006 | Gilead gets subpoena over HIV drug marketing:

Recently Intermune agreed to pay $36.9 million to settle charges related to off-label marketing efforts related to its drug Actimmune. It is reported they were touting its use in a fatal lung disorder and it is only approved for treatment of a bone disorder. Scios a division of Johnson & Johnson is also under investigation related to their drug Natrecor.

I know some folks who think that it should be illegal to prescribe drugs for off-label use. I tend to think the present system works but there is a need to make sure drug companies aren’t pushing the limits in terms of what their rugs can be used for. I don’t want to take away the ability of doctors to prescribe what they deem best for their patients and this is particularly true in the area of oncology.

One line of defense that needs to be worked on is doctors reporting of improper marketing efforts by companies. I have a suspicion that it occurs more often than many think and that it is just ignored by doctors instead of being brought to light. I know this comes up on occasions and is talked about in corporate meeting rooms but only behind closed doors and usually in the content of how far can we push this without getting caught. This problem is one of those “dirty little secrets” that exists and needs to be dealt with.

Other Resources

Drug Injury Watch: Off-label Use / Prescribing

Off-Label Imbroglio Latest Concern for Drugmakers

Genentech gets subpoena regarding drug marketing | The San Diego Union-Tribune
When Doctors Go Off-Label - Forbes.com

Technorati Tags: ,

Email Ed Vawter



Related Posts:
  • Follow up on Gilead to Acquire Mycogen
  • Pfizer to Cut 2,200 Marketing Jobs
  • Gilead to Acquire Mycogen
  • Spending on marketing vs R&D
  • Dr. Jarvik, Lipitor and Ethics

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Leave a Reply

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    December 2006
    S M T W T F S
    « Nov   Jan »
     12
    3456789
    10111213141516
    17181920212223
    24252627282930
    31  

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    35 queries. 2.005 seconds